Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions are no longer allowed – for now.

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...

Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...

A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

Semaglutide use in patients with Type 2 diabetes was associated with reduced postoperative complications after 90 days, according to a study in the March 2025 i ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...